• Mashup Score: 0

    About The Walk for PKD is the largest fundraising event for polycystic kidney disease (PKD), raising over $35 million since the year 2000. At the event, the PKD Foundation brings together patients, physicians, and researchers to strengthen the community for all impacted by PKD. When you ask your friends and family to support you and the Walk for PKD, 100% of each donation will fund life-saving…

    Tweet Tweets with this article
    • Yesterday was #PKDAwarenessDay Please consider donating to the @PKDFoundation to #endPKD https://t.co/skC7oxZWnY If you are in #SanDiego we look forward to seeing you at the #walktoendPKD on October 8th @PKDFSanDiego #ADPKD #ARPKD https://t.co/iHt2xvj4Ef

  • Mashup Score: 1

    Glycosphingolipids are a class of membrane lipids that regulate numerous cellular processes, including membrane organization, proliferation, cell cycle regulation, apoptosis, transport, migration, and inflammatory signaling.1 Dysregulation of this critical pathway in polycystic kidney disease (PKD) was first reported several decades ago. In the cpk/cpk mouse model, which exhibits renal pathology similar to human autosomal recessive PKD, levels of glucosylceramide (GL-1) and lactosylceramide were greater, ceramide levels were higher, and glucosylceramide synthase (GCS) activity was elevated as compared to control kidneys, suggesting the sphingolipids may play a role in disease progression (Fig 1).

    Tweet Tweets with this article
    • @RonGansevoort @ABCrenalarena @bertperso Editorial by @CortneySteele and @KristenlNowak: Targeting Glycosphingolipid Metabolism in ADPKD: Another Roadblock for Treatment https://t.co/cB31jlkIp0 (FREE) @CU_Kidney #ADPKD https://t.co/Q83n3GdySq

  • Mashup Score: 3

    Dr. Allen Davidoff, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease

    Tweet Tweets with this article
    • Allen Davidoff, PhD, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease #ADPKD @XORTXinc #checkrare #rarediseases #XORTX https://t.co/WcCkqgoQKG

  • Mashup Score: 0

    The FDA granted orphan drug designation for Xorlo, a drug from Xortx Therapeutics Inc. intended to treat autosomal dominant polycystic kidney disease, according to the press release.“Orphan drug designation represents a major milestone for the company in pursuit of marketing approval for Xorlo, our proprietary formulation of oxypurinol, and the XRx-008 program for [autosomal dominant PKD]

    Tweet Tweets with this article
    • The FDA granted orphan drug designation for Xorlo, a drug from Xortx Therapeutics Inc. intended to treat autosomal dominant polycystic kidney disease. #ADPKD https://t.co/JJJ2ZOhwR8

  • Mashup Score: 0

    Dr. Allen Davidoff, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease

    Tweet Tweets with this article
    • Allen Davidoff, PhD, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease #ADPKD @XORTXinc #checkrare #rarediseases #XORTX https://t.co/WcCkqgoQKG

  • Mashup Score: 1

    Dr. Allen Davidoff, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease

    Tweet Tweets with this article
    • Allen Davidoff, PhD, CEO of XORTX Therapeutics, discusses two phase 3 studies set to launch in the next two years evaluating oxypurinol in patients with autosomal dominant polycystic kidney disease #ADPKD @XORTXinc #checkrare #rarediseases #XORTX https://t.co/WcCkqgoQKG